Multi-million pound loss for Dundee life sciences firm Exscientia
Dundee-based life sciences company Exscientia racked up a multi-million pound loss last year as it invested heavily in research and development.
Life Sciences
Dundee’s Exscientia to focus on rare diseases
A Dundee firm which is a world leader in the use of artificial intelligence (AI) to aid drug discovery will focus on finding cures for rare diseases with its latest pharma partnership.
Tay Cities Deal key to Dundee life sciences
Collaboration and the impact of the Tay Cities Deal were the talking points of the 19th annual BioDundee international conference yesterday.
Dundee firm could be worth more than £1 billion if listed on stock exchange
A Dundee life sciences firm could be valued at more than £1 billion if it lists on the stock exchange, a financial analyst has claimed.
Science world to visit city for long-running BioDundee conference
The world's science community is to descend on Dundee next month for one of the country's longest running industry festivals.
Dundee’s Exscientia signs $25m drug deal
Dundee-based life sciences firm Exscientia has received an upfront payment of $25 million to enter a new partnership with a global pharmaceutical firm.
Life sciences sector in Dundee earns parliamentary praise
The success of Dundee's life sciences sector has been hailed in the Scottish Parliament.
Dundee’s life sciences sector waiting ‘with bated breath’ for detail of Brexit negotiations
Professor Mike Ferguson, regius professor of life sciences and academic lead for research strategy at Dundee University, tells Michael Alexander about the challenges and opportunities facing the life sciences sector.
Major healthcare issues to be confronted at BioDundee conference
Global healthcare challenges and obstacles to the exporting of medical research and products will be debated when the 17th BioDundee conference gets under way today.
Dundee AIdrug design firm secures €250m deal
A Dundee University spin-out company has secured a potential €250 million pipeline of work after agreeing a deal with life sciences giant Sanofi.